What's new

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Jun 18, 2025 - 11:05
 0
Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Medicinal products for human use: monthly figures - May 2025

Next Article

Human medicines European public assessment report (EPAR): Xromi, hydroxycarbamid...

Related Posts

Nitrosamine impurities: guidance for marketing authorisation holders

Nitrosamine impurities: guidance for marketing authoris...

May 28, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Inaqovi, Cedazuridine, decitabine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0124/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 10, 2025  0

Veterinary medicines European public assessment report (EPAR): Biobhyo, Swine dysentery vaccine (inactivated), Status: Opinion

Veterinary medicines European public assessment report ...

Jun 13, 2025  0